Renexxion, LLC
Records under this name other than the patents Renexxion, LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 6 patents it holds.
Showing 1 to 6 of 6 · Back to Renexxion, LLC
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,326,787 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders Term ended Term ended Aug 31, 2026 · High confidence | Term ended | Term ended Aug 31, 2026 | High confidence |
| US 7,629,466 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders Term ended Term ended Aug 31, 2026 · Medium confidence | Term ended | Term ended Aug 31, 2026 | Medium confidence |
| US 7,176,218 | Stereoisomeric Compounds and Methods for the Treatment of Gastrointestinal and Central Nervous System Disorders Term ended Term ended Aug 21, 2025 · High confidence | Term ended | Term ended Aug 21, 2025 | High confidence |
| US 8,138,204 | Stereoisomeric Compounds and Methods for the Treatment of Gastrointestinal and Central Nervous System Disorders Term ended Term ended Aug 21, 2025 · High confidence | Term ended | Term ended Aug 21, 2025 | High confidence |
| US 7,282,509 | Stereoisomeric Compounds and Methods for the Treatment of Gastrointestinal and Central Nervous System Disorders Term ended Term ended May 27, 2025 · High confidence | Term ended | Term ended May 27, 2025 | High confidence |
| US 8,524,736 | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders Term ended Ended no later than Jan 7, 2025 · USPTO record | Term ended | Ended no later than Jan 7, 2025 | USPTO record |